Biologic
Jan 13, 2017
Biosimilars: A benchmark in Pharmaceutical Business
The high cost of pharmaceuticals, especially Biologics, has been proven as an issue in the battle to control healthcare costs. The Biologics Price Competition and the Innovation Act has put forward the generic competition of Biologics or what is popularly called the Biosimilars. Biosimilars have been available in th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
